GBT Stock Discussion (GUERBET)

Guerbet keeps cash-flow warning as China weighs on imaging sales

Guerbet ($GBT) reported revenue of €573.8 million for the first nine months of 2026, down 2.2% as reported and 1.3% at constant currencies and comparable scope. Third-quarter sales fell 3.6% on the comparable measure, with business outside China broadly flat. Changes to Chinese healthcare purchasing continued to depress demand, while Interventional Radiology grew 10.7% on the same comparable basis, partly offsetting weaker Diagnostic Imaging. The contrast-agent manufacturer retained its 2026 for

GBT

@tickerstat1 month ago

Guerbet reports loss as remediation costs pressure margins

Guerbet ($GBT) reported first-half revenue of €379.2 million, down 2.2% as reported but almost unchanged on a constant-currency, like-for-like basis. EBITDA fell to €30.6 million from €46.1 million, and the group recorded a €32.7 million net loss. Remediation at its Raleigh manufacturing site generated €14.3 million of exceptional costs. Net financial debt reached €355.9 million and leverage stood at 5.3 times. The imaging-products supplier retained its full-year targets, including an approximat